Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apilimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIKFYVE known ✓ | Q9Y2I7 | 5/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | SYK | P43405 | 2/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | FRK | P42685 | 1/20 | 1.00 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apilimod SCHEMBL426299 | 1.00 | PIKFYVE (1.00) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL29365634 | 1.00 | PIKFYVE (1.00) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL29387519 | 1.00 | PIKFYVE (1.00) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL426300 | 1.00 | PIKFYVE (1.00) | PIKFYVETYK2SYKIRAK4FES | |
| SCHEMBL18121499 | 0.97 | PIKFYVE (0.94) | PIKFYVETYK2SYKIRAK4FES | |
| SCHEMBL20507067 | 0.97 | PIKFYVE (0.94) | PIKFYVETYK2SYKIRAK4FES | |
| SCHEMBL18115419 | 0.96 | PIKFYVE (0.92) | PIKFYVETYK2SYKIRAK4FES | |
| SCHEMBL18115421 | 0.96 | PIKFYVE (0.92) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL3082382 | 0.95 | PIKFYVE (0.91) | PIKFYVETYK2SYKIRAK4FES | |
| Apilimod SCHEMBL3082380 | 0.95 | PIKFYVE (0.91) | PIKFYVETYK2SYKIRAK4FES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025030033-A1 | APILIMOD COMPOSITIONS AND METHODS OF USE | ORPHAI THERAPEUTICS INC. (US) | 2025-02-06 | — | — | WO | disclosed |
| US-20240374523-A1 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | ACADIA WOODS PARTNERS, LLC | 2024-11-14 | — | — | US | disclosed |
| WO-2024191947-A1 | PIKFYVE INHIBITOR COMBINATION THERAPY | ORPHAI THERAPEUTICS INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024107448-A1 | APILIMOD COMBINATION THERAPY | ORPHAI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4351585-A1 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | Orphai Therapeutics Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4308103-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | AI Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2024015281-A1 | APILIMOD COMBINATION THERAPY | AI Therapeutics, Inc. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015286-A1 | APILIMOD COMBINATION THERAPY | AI Therapeutics, Inc. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2022261499-A1 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | AI Therapeutics, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-4100016-A1 | ANTI-VIRAL COMPOSITIONS AND METHODS OF USE | AI Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022197667-A1 | ANTIVIRAL COMPOSITIONS AND METHODS | YOUNG PETER R (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-3956358-A1 | ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR COMBINATION THERAPY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374523-A1 | STABILIZED APILIMOD COMPOSITIONS AND USES THEREOF | PRNP, PARK7, API5 | PIKFYVE 362/4885TYK2 3975/4885SYK 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.